# AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

> **NCT04432857** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Adlai Nortye Biopharma Co., Ltd.** · enrollment: 63 (actual)

## Conditions studied

- Triple-negative Breast Cancer
- NSCLC, Squamous or Non-Squamous
- Urothelial Carcinoma of the Bladder
- Microsatellite Stable (MSS) Colorectal Cancer (CRC)
- Cervical Cancer

## Interventions

- **DRUG:** AN0025
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04432857
- **Lead sponsor:** Adlai Nortye Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-20
- **Primary completion:** 2024-05-31
- **Final completion:** 2025-01-30
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2024-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04432857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04432857, "AN0025 and Pembrolizumab Combination in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04432857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*